Zulu
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Imikhiqizo Izigaba
Imikhiqizo efakiwe
Amathebulethi eLenopril Anika Amandla Ukulawula Umfutho Wegazi kanye Nempilo Yenhliziyo

Amathebulethi eLenopril Anika Amandla Ukulawula Umfutho Wegazi kanye Nempilo Yenhliziyo
I-Telmisartan I-antihypertensive Protecting renal engcono

I-Telmisartan I-antihypertensive Protecting renal engcono
I-Flumazenil I-GABAA Receptor Antagonist ekhethiwe kanye nezicelo zayo zokwelapha

I-Flumazenil I-GABAA Receptor Antagonist ekhethiwe kanye nezicelo zayo zokwelapha
I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers

I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers
I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control

I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control
I-Cisapride Gastric Stimulant for Indigestion and Digestive Disorders

I-Cisapride Gastric Stimulant for Indigestion and Digestive Disorders
I-YK-11 I-SARM Enamandla Yokwakhiwa Kwemisipha, Ukuzuza Amandla, kanye Ne-Myostatin Inhibition

I-YK-11 I-SARM Enamandla Yokwakhiwa Kwemisipha, Ukuzuza Amandla, kanye Ne-Myostatin Inhibition
I-Ostarine (MK-2866) I-SARM Eguquguqukayo Yokukhula Kwemisipha, Ukulahlekelwa Kwamafutha, Nokubuyiswa Komzimba

I-Ostarine (MK-2866) I-SARM Eguquguqukayo Yokukhula Kwemisipha, Ukulahlekelwa Kwamafutha, Nokubuyiswa Komzimba
I-MK-677 Inhlanganisela Eyingqayizivele Yokukhula Kwemisipha, Ukukhuthazela, Nokubuyiselwa

I-MK-677 Inhlanganisela Eyingqayizivele Yokukhula Kwemisipha, Ukukhuthazela, Nokubuyiselwa
0102030405
I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers
I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers
I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers
I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers

I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers

Intengo: USD 50-60/kg

  • Igama Lomkhiqizo I-Dabrafenib
  • Inombolo ye-CAS. 1195765-45-7
  • MF I-C23H20F3N5O2S2
  • MW 519.561
  • EINECS 1592732-453-0
  • Ukuminyana 1.443
  • Iphuzu elibilayo 653.726 °C ku-760 mmHg
Xhumana nathi
imininingwane yomkhiqizo

Incazelo Eningiliziwe

I-Dabrafenib iyi-oral bioavailable inhibitor ye-B-raf (BRAF) protein futhi isetshenziswa njengomuthi wokulwa nomdlavuza. Iqondise ngokukhetha umdlavuza ohambisana nenguqulo eguquliwe yofuzo lwe-BRAF. Lesi sihloko sihlola indlela yokusebenza, izinkomba zomtholampilo, nokusetshenziswa kwe-dabrafenib ekwelapheni umdlavuza ohlukahlukene.

I. Ukuqonda i-Dabrafenib:
A. Inhibitor ye-B-raf (BRAF) protein
B. Indlela yokwenza: Ukuvimbela ukubonakaliswa kwephrotheni okungajwayelekile kanye nokulawula ukukhula kwamaseli

17159473034104h3

II. Izinkomba Zomtholampilo:

A. I-Monotherapy:

I-melanoma engabukeki noma ye-metastatic enenguquko ye-BRAF V600E

B. Ukwelashwa okuhlanganisiwe ne-trametinib:

I-BRAF V600E-positive engasabukeki noma i-metastatic melanoma

Umdlavuza wamaphaphu we-Metastatic ongewona omncane

Umdlavuza we-thyroid we-Metastatic anaplastic

Izimila eziqinile ezingenakuvinjelwa noma ze-metastatic


III. Indlela Yesenzo:

A. Ukubopha okukhethiwe kanye nokuvinjwa kwe-B-raf

B. Ukuvinjelwa kokusabalala kweseli yesimila ngofuzo oluguquliwe lwe-BRAF


IV. Ukwelashwa komdlavuza we-thyroid:

A. Uhlobo oluthile lomdlavuza wegilo olusabalele ezicutshini eziseduze noma kwezinye izingxenye zomzimba

B. Ukumelana nokwelashwa kwangaphambilini


Ikilasi le-V. Kinase Inhibitor:

A. Dabrafenib njengelungu le-kinase inhibitors

B. Ukuvimbela isenzo samaprotheni esingavamile ukuvimbela ukuphindaphindeka kwamangqamuzana omdlavuza


I-Dabrafenib iwukwelapha okuhlosiwe okusetshenziselwa ukwelapha umdlavuza oguquliwe we-BRAF. Njengesivimbeli seprotheni ye-B-raf (BRAF), iqondise ngokukhetha amaseli wesimila aqukethe isakhi sofuzo se-BRAF esiguquliwe, avimbele ukwanda kwawo. I-Dabrafenib ihloselwe i-melanoma engahlanjululwa noma ye-metastatic, umdlavuza wamaphaphu wengqamuzana ongewona omncane, umdlavuza wegilo we-anaplastic, kanye nezimila eziqinile ezingabukeki noma ezine-metastatic. Ukwelashwa okuhlangene ne-trametinib kwandisa ukusetshenziswa kwayo. Ngokuqonda izinguquko ezithile zofuzo kumangqamuzana omdlavuza, izindlela zokwelapha ezihlosiwe njenge-dabrafenib zidlala indima ebalulekile ekwenzeni ngcono imiphumela yokwelashwa kanye nokuvimbela ukusabalala kwamangqamuzana omdlavuza.

Ukucaciswa

1715947563669qd1